[September 03, 2009] Reportlinker Adds Synthetic Biology: Emerging Global Markets Report Tweet NEW YORK, Sept 03, 2009 /PRNewswire-USNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Synthetic Biology: Emerging Global Markets http://www.reportlinker.com/p0128136/Synthetic-Biology-Emerging-Global-Markets.html This Report: The global market for synthetic biology generated $233.8 million in 2008. This is expected to increase to $2.4 billion in 2013, for a compound annual growth rate (CAGR) of 59.8%. The chemicals and energy segment has the largest share of the market, worth $80.6 million in 2008. This should reach $1.6 billion in 2013, for a CAGR of 81.6%. The biotechnology and pharmaceuticals segment is the second-largest market segment, worth 80.3 million in 2008. This segment is projected to increase at a CAGR of 49.2% to reach $594 million in 2013. Chapter-1: SUMMARY SUMMARY 5 SUMMARY TABLE GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS) 6 SUMMARY FIGURE GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY INDUSTRY, 2006-2013 ($ MILLIONS) 6 SUMMARY (CONTINUED) 7 Chapter-2: OVERVIEW SYNTHETIC BIOLOGY TECHNOLOGIES COVERED IN THIS REPORT 8 TABLE 1 SCOPE OF THIS REPORT 8 WHAT IS SYNTHETIC BIOLOGY? 8 WHAT IS SYNTHETIC BIOLOGY (CONTINUED) 9 DEVELOPMENT STAGE OF SYNTHETIC BIOLOGY 10 FORCES DRIVING SYNTHETIC BIOLOGY MARKET GROWTH 10 TABLE 2 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 10 TABLE 2 (CONTINUED) 11 GLOBAL MARKET POTENTIAL FOR SYNTHETIC BIOLOGY PRODUCTS 12 TABLE 3 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END USER, THROUGH 2013 ($ MILLIONS) 13 TABLE 4 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS) 14 LIFE CYCLE STATUS OF SYNTHETIC BIOLOGY TECHNOLOGIES 14 TABLE 5 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE 15 THE SYNTHETIC BIOLOGY INDUSTRY 15 TABLE 6 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET FOCUS 16 THE SYNTHETIC BIOLOGY INDUSTRY (CONTINUED) 17 Chapter-3: SYNTHETIC BIOLOGY TECHNOLOGIES INTRODUCTION 18 DEFINITION OF SYNTHETIC BIOLOGY 18 TABLE 7 SYNTHETIC BIOLOGY DEFINITIONS 18 HISTORY OF SYNTHETIC BIOLOGY 18 TABLE 8 SYNTHETIC BIOLOGY HISTORY 19 PARADIGM SHIFT IN BIOLOGY 20 TABLE 9 PARADIGM SHIFT OF BIOLOGY 20 TABLE 10 GENETIC ENGINEERING AND SYNTHETIC BIOLOGY COMPARED 21 FIGURE 1 SCALE OF SYNTHETIC BIOLOGY 22 SYNTHETIC BIOLOGY TECHNOLOGY OVERVIEW 23 TABLE 11 SYNTHETIC BIOLOGY APPLICATIONS BY TECHNOLOGY 23 ENABLING TECHNOLOGIES 24 TABLE 12 IMPORTANCE OF ENABLING TECHNOLOGIES 24 COSTS OF DNA SYNTHESIS AND SEQUENCING 25 FIGURE 2 DNA SYNTHESIS AND SEQUENCING COSTS, 1990-2008 ($) 25 FIGURE 3 HUMAN GENOME SEQUENCING COSTS, 1990-2015 ($) 26 DNA SYNTHESIS TECHNOLOGIES 27 FIGURE 4 SIMPLIFIED SCHEMATIC OF GENE SYNTHESIS TECHNOLOGY 27 DNA Synthesis . . . (Continued) 28 TABLE 13 COMPARISON OF GENE SYNTHESIS TECHNOLOGIES 29 PCR-Based Approaches 29 Solid-Phase Approaches 30 MICROFLUIDICS TECHNOLOGIES 31 TABLE 14 IMPORTANCE OF MICROFLUIDICS TECHNOLOGIES IN SYNTHETIC BIOLOGY 31 DNA Microarrays--Oligos Synthesis 31 TABLE 15 MICROARRAY TYPES 32 TABLE 16 DNA MICROARRAY PLATFORM FEATURES 32 TABLE 17 DNA MICROARRAY PLATFORM COMPARISON FOR MAJOR MANUFACTURERS 33 TABLE 17 (CONTINUED) 34 DNA Microarrays--. . .(Continued) 35 FIGURE 5 MICROARRAYS IN GENE SYNTHESIS 36 DNA SEQUENCING TECHNOLOGIES 36 DNA Sequencing TECHNOLOGIES (continued) 37 FIGURE 6 SEQUENCING THROUGHPUT TREND, 1977-2008 38 FIGURE 7 DNA SEQUENCING TECHNOLOGIES 39 BIOINFORMATICS TECHNOLOGIES 40 TABLE 18 SYNTHETIC BIOLOGY BIOINFORMATICS TECHNOLOGIES 41 BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS TECHNOLOGIES 41 TABLE 19 NUCLEIC ACIDS, GENES, AND GENOMES 41 SYNTHETIC GENES 42 TABLE 20 SYNTHETIC GENES AS MOLECULAR BIOLOGY TOOL 42 Synthetic Genes (Continued) 43 TABLE 21 SYNTHETIC GENES VERSUS PCR CLONING 44 BIOBRICKS/IGEM PARTS 45 TABLE 22 BIOBRICKS/IGEM PARTS 46 FIGURE 8 ROLE OF PROMOTERS AND REPORTERS IN SYNTHETIC BIOLOGY SYSTEMS 47 MINIMAL GENOMES AND CHASSIS ORGANISMS 48 TABLE 23 ATTRIBUTES OF A MINIMAL GENOME 48 Minimal Genomes and . . . (Continued) 49 CASE STUDY: MINIMAL E.COLI GENOME 50 Role of Directed Evolution in Designing Biologic Parts 50 ENABLED TECHNOLOGIES 51 OVERVIEW 51 TABLE 24 ENABLED TECHNOLOGIES: EXISTING AND NEAR-TERM APPLICATIONS 51 Pathway Engineering 52 FIGURE 9 HOW SYNTHETIC BIOLOGY CREATES ENABLED PRODUCTS 52 TABLE 25 METABOLIC ENGINEERING FOR ARTEMISINIC ACID 53 Synthetic Microbial Consortia 54 TABLE 26 APPLICATIONS FOR SYNTHETIC MICROBIAL CONSORTIA 55 BIOFUELS TECHNOLOGIES 56 Biofuels Feedstocks 56 TABLE 27 ENERGY BALANCE OF SELECTED FIRST-GENERATION BIOFUEL FEEDSTOCKS 57 Advanced-Generation Biofuels 57 TABLE 28 FIRST- AND ADVANCED-GENERATION BIOFUELS COMPARED 58 Cellulosic Biomass 59 FIGURE 10 APPROXIMATE COMPOSITION OF CELLULOSIC BIOMASS (%) 59 TABLE 29 SYNTHETIC BIOLOGY STRATEGIES FOR CONVERTING CELLULOSIC BIOMASS INTO ETHANOL 60 Biofuels Types 61 TABLE 30 EFFICIENCY OF VARIOUS FUELS 61 Cellulosic Ethanol 62 FIGURE 11 CELLULOSIC ETHANOL PRODUCTION SCHEMATIC 62 TABLE 31 CORN ETHANOL COST TARGETS, 2009 ($/GAL. OF ETHANOL) 63 FIGURE 12 ESTIMATED 25 MGY CELLULOSIC ETHANOL PLANT COSTS (%) 64 Biodiesel 65 TABLE 32 IODINE NUMBER OF VARIOUS OILS 66 Other Biofuels 66 Role of Genetic Engineering and Synthetic Biology in Biofuels 66 TABLE 33 CONTRIBUTION OF SYNTHETIC BIOLOGY TO BIOFUELS 67 Chapter-4: SYNTHETIC BIOLOGY APPLICATIONS INTRODUCTION 68 ENABLING TECHNOLOGIES 68 TABLE 34 SYNTHETIC BIOLOGY PRODUCTS IMPACTED BY ENABLING TECHNOLOGIES 68 BIOLOGIC COMPONENTS AND INTEGRATED SYSTEMS APPLICATIONS 69 TABLE 35 BIOLOGICAL COMPONENTS AND INTEGRATED SYSTEMS NEAR-TERM APPLICATIONS 69 SYNTHETIC GENE APPLICATIONS 70 TABLE 36 SYNTHETIC GENES NEAR-TERM APPLICATIONS 70 Synthetic Gene Applications (Continued) 71 Synthetic Gene Applications (Continued) 72 BIOBRICKS/IGEM PARTS APPLICATIONS 73 INTEGRATED SYSTEMS APPLICATIONS 73 Synthetic Cells and Tissues 74 ENABLED PRODUCTS APPLICATIONS 75 TABLE 37 ENABLED PRODUCTS NEAR-TERM APPLICATIONS 75 APPLICATIONS BY END-USER INDUSTRY 76 RESEARCH AND DEVELOPMENT APPLICATIONS 76 TABLE 38 RESEARCH & DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY PRODUCTS 76 PHARMACEUTICALS APPLICATIONS 77 TABLE 39 DRUG DISCOVERY AND DEVELOPMENT APPLICATIONS FOR SYNTHETIC BIOLOGY PRODUCTS 77 Pharmaceuticals Applications (Continued) 78 TABLE 40 PIPELINE OF SYNTHETIC BIOLOGY-ENABLED DRUGS 79 ENERGY APPLICATIONS 80 TABLE 41 ETHANOL AND BIODIESEL FEEDSTOCKS AND PRODUCTION PROCESSES 80 TABLE 42 ETHANOL AND BIODIESEL COMMON BLENDS 81 TABLE 43 FIRST-GENERATION FUEL ETHANOL GLOBAL PRODUCTION AND GOALS, 2007 (MILLION GALS.) 82 TABLE 44 FIRST-GENERATION BIODIESEL PRODUCTION AND GOALS, 2007 (MILLION GALS.) 83 United States 83 FIGURE 13 RENEWABLE FUELS STANDARDS, UNITED STATES, 2008-2013 (BILLION GALS./ YR) 84 TABLE 45 DOE FUNDING FOR CELLULOSIC BIOFUELS, 2007-2011 ($ MILLIONS) 85 Canada 86 Brazil 87 CHEMICAL INDUSTRY APPLICATIONS 87 Chemical Industry Applications (Continued) 88 Chapter-5: SYNTHETIC BIOLOGY INDUSTRY INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN 89 FIGURE 14 INDUSTRIAL BIOTECHNOLOGY VALUE CHAIN WITH SYNTHETIC BIOLOGY LEVERAGE POINTS 90 INDUSTRY STRUCTURAL FORCES 91 TABLE 46 SYNTHETIC BIOLOGY INDUSTRY STRUCTURAL FORCES 91 INDUSTRY STRUCTURAL FORCES (CONTINUED) 92 PRODUCTS AND TECHNOLOGY LIFE CYCLE 93 TABLE 47 SYNTHETIC BIOLOGY PRODUCTS AND TECHNOLOGY LIFE CYCLE STAGE 93 INDUSTRY COMPETITOR POSITIONING 94 TABLE 48 SYNTHETIC BIOLOGY KEY COMPETITORS BY MARKET FOCUS 95 GENE SYNTHESIS INDUSTRY 96 GENE SYNTHESIS WORKFLOW 96 TABLE 49 GENE SYNTHESIS WORKFLOW 96 Gene Synthesis Workflow (Continued) 97 GENE SYNTHESIS COMPETITOR STRATEGIES 98 FIGURE 15 SYNTHETIC GENE COMPANY ESTIMATED MARKET SHARES, 2008 (%) 99 Gene Synthesis . . . (Continued) 100 TABLE 50 SYNTHETIC GENE KEY COMPETITOR STRATEGIES 101 Gene Synthesis . . . (Continued) 102 Gene Synthesis Value Chain 103 Synthetic Gene Market Segments 104 Automated, Standardized Market Segment 104 Value-Added Market Segments 104 TABLE 51 GENE SYNTHESIS MARKET FACTORS OF DIFFERENTIATION 105 BIOFUELS INDUSTRY 106 COMPETITIVE DIFFERENTIATION 106 FEEDSTOCKS 107 TABLE 52 BIOFUELS: FEEDSTOCKS, PRODUCTION, AND PRODUCTS 107 FIGURE 16 BIOFUELS FEEDSTOCKS: RELATIVE COSTS AND VOLUMES 108 Sugars/Starches 108 Vegetable Oils 109 Biomass 109 Algae 109 TABLE 53 BIODIESEL YIELD OF SELECTED CROPS (GALS./ACRE/YR.) 109 CO2 110 CELLULOSIC ETHANOL INDUSTRY 111 TABLE 54 CELLULOSIC ETHANOL PLANTS (MGY) 111 Cellulosic Ethanol Industry (Continued) 112 BIOFUELS COMPETITOR STRATEGIES 113 TABLE 55 SYNTHETIC BIOLOGY-BASED BIOFUELS COMPANY STRATEGIES 114 TABLE 55 (CONTINUED) 115 Agrivida 115 Amyris 116 BP 116 DuPont 116 Gevo 116 LS9 117 Mascoma 117 OpX Biotechnologies 117 Sequesco 118 Solazyme 118 Synthetic Genomics 118 Verdezyne 118 Verenium 119 ROLE OF BIOFUELS FOUNDERS AND INVESTORS 119 TABLE 56 ROLE OF INVESTORS AND FOUNDERS IN BIOFUELS COMPANIES 119 ENZYMES INDUSTRY 120 TABLE 57 ENZYME COMPANY KEY ALLIANCES 121 PHARMACEUTICALS INDUSTRY 122 TABLE 58 PHARMACEUTICALS COMPANY STRATEGIES 122 INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES 123 TABLE 59 INDUSTRY ACQUISITIONS, 2006-2008 123 TABLE 60 SYNTHETIC BIOLOGY STRATEGIC ALLIANCES, 2006-2009 124 TABLE 60 (CONTINUED) 125 TABLE 60 (CONTINUED) 126 BIODEFENSE ISSUES 127 TABLE 61 FUTURE SYNTHETIC BIOLOGY SECURITY REGULATIONS 127 SUPPORTING INDUSTRY ORGANIZATIONS 128 TABLE 62 SYNTHETIC BIOLOGY ENABLING ORGANIZATIONS 128 TABLE 62 (CONTINUED) 129 SUPPORTING INDUSTRY . . . (CONTINUED) 130 FIGURE 17 GROWTH IN IGEM (NUMBER) 131 Chapter-6: SYNTHETIC BIOLOGY MARKETS GROWTH DRIVING FORCES 132 TABLE 63 SYNTHETIC BIOLOGY GROWTH DRIVING FORCES 133 FIGURE 18 NIH BUDGET OUTLAYS, 2000-2009 ($ BILLIONS) 134 FIGURE 19 SYNTHETIC BIOLOGY RESEARCH PUBLICATIONS, 2000-2008 (NUMBER) 135 MARKET FORECASTS 136 FIGURE 20 MARKET FORECAST SCENARIO TABLE 136 SYNTHETIC BIOLOGY MARKETS BY INDUSTRY 137 Summary 137 TABLE 64 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY END USER, THROUGH 2013 ($ MILLIONS) 137 R&D Market 138 TABLE 65 GLOBAL VALUE OF R&D MARKET BY APPLICATION, THROUGH 2013 ($ MILLIONS) 138 Biotechnology and Pharmaceuticals Market 139 TABLE 66 GLOBAL VALUE OF BIOTECHNOLOGY AND PHARMACEUTICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 140 Chemicals Market 141 TABLE 67 GLOBAL VALUE OF CHEMICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 141 Energy Market 142 TABLE 68 GLOBAL VALUE OF ENERGY MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 142 FIGURE 21 S-CURVE FOR SECOND-GENERATION BIOFUELS 143 TABLE 69 WORLD BIODIESEL PRODUCTION AND CAPACITY TRENDS, 2002-2008 (MILLIONS TONS/YR) 144 TABLE 70 GLOBAL BIOFUELS SUPPLY BY PRODUCT CLASS, THROUGH 2013 (KBOED) 145 FIGURE 22 GLOBAL BIOFUELS MARKET, 2013 (GALS./YR.) 145 FIGURE 22 (CONTINUED) 146 FIGURE 23 GLOBAL CELLULOSIC SECOND-GENERATION BIOFUELS MARKET, 2013 (GALS./YR) 146 FIGURE 23 (CONTINUED) 147 FIGURE 24 UNITED STATES BIOFUELS MARKET GOALS, 2022 (%) 147 SYNTHETIC BIOLOGY MARKETS BY PRODUCT TYPE 148 Summary 148 TABLE 71 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 148 Summary (Continued) 149 Enabling Products Market 150 TABLE 72 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLING PRODUCTS MARKET, THROUGH 2013 ($ MILLIONS) 150 Biological Parts Market 151 TABLE 73 GLOBAL VALUE OF DNA SYNTHESIS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 151 TABLE 74 GLOBAL VALUE OF BIOLOGIC PARTS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 152 Standardized Market Segment 152 Value-Added Market Segments 152 TABLE 75 GLOBAL VALUE OF BIOLOGIC PARTS MARKET BY END USER INDUSTRY, THROUGH 2013 ($ MILLIONS) 153 TABLE 76 GLOBAL VALUE OF BIOLOGIC PARTS BY SUPPLIER TYPE, THROUGH 2013 ($ MILLIONS) 154 TABLE 77 HOMEBREW VERSUS COMMERCIAL COST COMPARISON FOR SYNTHESIZING A TYPICAL 714 BP GFP GENE ($) 155 Integrated Systems Market 156 TABLE 78 GLOBAL VALUE OF SYNTHETIC BIOLOGY INTEGRATED SYSTEMS MARKET BY TYPE, THROUGH 2013 ($ MILLIONS) 156 Enabled Products Market 156 TABLE 79 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED PRODUCTS MARKET BY INDUSTRY, THROUGH 2013 ($ MILLIONS) 157 TABLE 80 GLOBAL VALUE OF ENABLED R&D MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 158 TABLE 81 GLOBAL VALUE OF ENABLED PHARMACEUTICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 159 TABLE 82 GLOBAL VALUE OF ENABLED CHEMICALS MARKET BY PRODUCT TYPE, THROUGH 2013 ($ MILLIONS) 160 TABLE 82 (CONTINUED) 161 TABLE 83 GLOBAL VALUE OF SYNTHETIC BIOLOGY-ENABLED ENERGY MARKET BY FUEL TYPE, THROUGH 2013 ($ MILLIONS) 162 SYNTHETIC BIOLOGY MARKET BY GEOGRAPHIC REGION 163 Summary 163 TABLE 84 GLOBAL VALUE OF SYNTHETIC BIOLOGY MARKET BY GEOGRAPHIC REGION, THROUGH 2013 ($ MILLIONS) 164 Importance of Geography to Fuels Markets 165 Importance of Geography . . . (Continued) 166 Chapter-7: PATENT STATUS INTRODUCTION 167 FOUNDATIONAL PATENTS 167 TABLE 85 SYNTHETIC BIOLOGY FOUNDATIONAL PATENTS 168 SYNTHETIC BIOLOGY INDUSTRY PATENT ANALYSIS 169 SYNTHETIC BIOLOGY INDUSTRY (continued) 170 FIGURE 25 NUMBER OF PATENTS BY COMPANY 171 FIGURE 25 (CONTINUED) 172 TABLE 86 PATENT DESCRIPTION BY COMPANY 173 FIGURE 26 SYNTHETIC BIOLOGY PATENTS BY COMPANY AND SUBCLASS (NUMBER OF PATENTS) 174 FIGURE 26 (CONTINUED) 175 LITIGATION STATUS 176 TABLE 87 IP LITIGATION STATUS 176 IP STRATEGY OF SELECTED SYNTHETIC BIOLOGY COMPANIES 177 METABOLIX 177 DUPONT 178 GENEART 178 FEBIT 179 Chapter-8: COMPANY PROFILES AGRIVIDA 180 AMYRIS BIOTECHNOLOGIES, INC. 180 TABLE 88 AMYRIS BIODIESEL ADVANTAGES 181 ATG BIOSYNTHETICS GMBH 182 BASF AG 183 BIO BASIC, INC. 184 BIOCAT GMBH 184 BIONEER CORP. 185 BIONEXUS, INC. 185 BIO S&T, INC. 186 BIOTICA TECHNOLOGY, LTD. 186 BIOTICA TECHNOLOGY, LTD. (CONTINUED) 187 TABLE 89 STRUCTURE-FUNCTION APPROACH FOR RAPAMYCIN 188 TABLE 90 BIOTICA PROJECTS PIPELINE 189 BLUE HERON BIOTECHNOLOGIES 190 BRISTOL-MYERS SQUIBB 190 BRISTOL-MYERS SQUIBB (CONTINUED) 191 BRITISH PETROLEUM 192 CELLICON BIOTECHNOLOGIES, INC. 193 CODEXIS, INC. 194 CODON DEVICES, INC. 195 DANISCO A/S 195 DNA 2.0 196 TABLE 91 DNA2.0 STRATEGIC ALLIANCES 197 DRATHS CORP. 198 DUPONT 199 DUPONT (CONTINUED) 200 DYADIC INTERNATIONAL, INC. 201 ENTELECHON GMBH 201 EPOCH BIOLABS, INC. 202 ERAGEN BIOSCIENCES, INC. 203 EUROFINS MEDIGENOMIX GMBH 203 EUROFINS MWG OPERON 204 FEBIT SYNBIO GMBH 204 GENEART AG 205 TABLE 92 GENEART MAJOR STRATEGIC ALLIANCES 206 GENEART AG (CONTINUED) 207 GENEMED SYNTHESIS, INC. 208 GENSCRIPT CORP. 208 GENEWORKS PTY, LTD. 208 GEVO, INC. 209 TABLE 93 GEVO ISOBUTANOL PRODUCTION FORECAST (GALS./YR.) 209 HELICOS BIOSCIENCES CORP. 210 HELICOS BIOSCIENCES CORP. (CONTINUED) 211 HELICOS BIOSCIENCES CORP. (CONTINUED) 212 INTEGRATED DNA TECHNOLOGIES 213 ILLUMINA, INC. 213 ILLUMINA, INC. (CONTINUED) 214 INSTITUTE FOR ONEWORLD HEALTH 215 IOGEN CORP. 216 JOULE BIOTECHNOLOGIES, INC. 216 KHOSLA VENTURES 216 TABLE 94 KHOSLA VENTURES BIOFUELS INVESTMENT PORTFOLIO 217 LC SCIENCES 217 LIFE TECHNOLOGIES 218 LIFE TECHNOLOGIES (CONTINUED) 219 LS9, INC. 220 MASCOMA 221 TABLE 95 MASCOMA INTELLECTUAL PROPERTY STATUS 222 MAXYGEN 223 MERCK & CO. 224 METABOLIX, INC. 225 TABLE 96 METABOLOMIX BUSINESS STRATEGY 225 METRIGEN, INC. 226 NOVOZYMES A/S 227 OMEGA BIO-TEK, INC. 227 OPX BIOTECHNOLOGIES, INC. 228 PACIFIC BIOSCIENCES 229 PFIZER 230 PROTOLIFE SRL 231 QTEROS 232 ROCHE LIFE SCIENCES 232 ROCHE LIFE SCIENCES (CONTINUED) 233 ROYAL DSM N.V. 234 SANGAMO BIOSCIENCES, INC. 234 SANGAMO BIOSCIENCES, INC. (CONTINUED) 235 SANOFI AVENTIS 236 SCARAB GENOMICS, LLC 237 SEQUESCO 238 SLONING BIOTECHNOLOGY, GMBH 238 SOLAZYME, INC. 239 TABLE 97 SOLAZYME STRATEGIC ALLIANCES 240 SYNTHETIC GENOMICS 240 SYNTHETIC GENOMICS (CONTINUED) 241 TABLE 98 SYNTHETIC GENOMICS STRATEGIC ALLIANCES 242 VERDEZYNE 242 TABLE 99 VERDEZYNE STRATEGIC COLLABORATIONS 243 VERENIUM CORP. 244 VERENIUM CORP. (CONTINUED) 245 To order this report: Synthetic Biology: Emerging Global Markets http://www.reportlinker.com/p0128136/Synthetic-Biology-Emerging-Global-Markets.html More market research reports here! Nicolas Bombourg Reportlinker Email: [email protected] US: (805)652-2626 Intl: +1 805-652-2626 SOURCE Reportlinker http://www.reportlinker.com [ Back To TMCnet.com's Homepage ]